$4.76
0.85% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US53630X1046
Symbol
LPCN
Sector
Industry

Lipocine, Inc. Stock price

$4.76
+0.31 6.97% 1M
-2.99 38.58% 6M
+1.97 70.61% YTD
+1.81 61.36% 1Y
-12.92 73.08% 3Y
-1.28 21.15% 5Y
-83.30 94.59% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.04 0.85%
ISIN
US53630X1046
Symbol
LPCN
Sector
Industry

Key metrics

Market capitalization $25.46m
Enterprise Value $5.64m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.73
P/S ratio (TTM) P/S ratio 3.28
P/B ratio (TTM) P/B ratio 1.33
Revenue growth (TTM) Revenue growth 14,014.81%
Revenue (TTM) Revenue $7.76m
EBIT (operating result TTM) EBIT $-5.46m
Free Cash Flow (TTM) Free Cash Flow $-5.03m
Cash position $19.82m
EPS (TTM) EPS $-0.76
P/E forward negative
P/S forward 2.81
EV/Sales forward 0.62
Short interest 2.07%
Show more

Is Lipocine, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Lipocine, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Lipocine, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Lipocine, Inc. forecast:

Buy
100%

Financial data from Lipocine, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
7.76 7.76
15,420% 15,420%
100%
- Direct Costs 0.03 0.03
50% 50%
0%
7.73 7.73
25,667% 25,667%
100%
- Selling and Administrative Expenses 5.23 5.23
13% 13%
67%
- Research and Development Expense 7.92 7.92
22% 22%
102%
-5.42 -5.42
63% 63%
-70%
- Depreciation and Amortization 0.03 0.03
50% 50%
0%
EBIT (Operating Income) EBIT -5.46 -5.46
63% 63%
-70%
Net Profit -4.06 -4.06
75% 75%
-52%

In millions USD.

Don't miss a Thing! We will send you all news about Lipocine, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lipocine, Inc. Stock News

Neutral
PRNewsWire
12 days ago
SALT LAKE CITY , Dec. 17, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track Designation to LPCN 1148 as a treatment for sarcopenia in patients with decompensated cirrhosis. L...
Neutral
PRNewsWire
about one month ago
SALT LAKE CITY , Nov. 18, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the publication and discussion of a manuscript "Oral LPCN 1148 Improves Sarcopenia and Hepatic Encephalopathy in Male Patients with Cirrhosis: a randomized, placebo-control...
Neutral
PRNewsWire
about 2 months ago
SALT LAKE CITY , Nov. 7, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the third quarter and nine months ended September 30, 2024 and provided a corporate update. Neuroactive Steroids LPCN 1154, oral brexanolone, is being ...
More Lipocine, Inc. News

Company Profile

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development for the delivery of drugs using proprietary delivery technology. The firm involves in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Mahesh Patel
Employees 17
Founded 2011
Website www.lipocine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today